CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis
September 8, 2026
Disease activity fell in all six participants in a phase I trial, with three achieving sustained drug-free remission during follow-up
2 min read
False
Advertisement
Research News
CAR T Before Surgery Improves Glioblastoma Control in Mice
September 7, 2026
Study finds that tumor resection creates a more immunosuppressive environment and that earlier CAR T cell treatment prolongs survival
2 min read
This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement
August 31, 2026
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
4 min read
This Week’s CGT News: Antifreeze Sugars Protect CAR T Cells
August 24, 2026
A new preservation method could remove a major barrier to treatment, the FDA approves the first gene therapy for GSDIa, and ultrasound directs CAR T cells toward solid tumors
5 min read
This Week’s CGT News: T-Cell Therapy Clears Pediatric Solid Tumor
August 17, 2026
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
3 min read
This Week’s CGT News: In Vivo CAR T Draws Major Investment
August 10, 2026
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
3 min read
This Week’s CGT News: Gene-Editing Trial Death Raises Concerns
August 3, 2026
A previously undisclosed death in China raises questions about gene-editing oversight, deramiocel meets its Phase 3 Duchenne endpoint, and researchers identify a source of CAR NK dysfunction
4 min read
This Week’s CGT News: Off-the-Shelf CAR T Tackles Kidney Cancer
July 27, 2026
Allogeneic CAR T produces durable responses in advanced kidney cancer, the FDA clears a CD22-directed in vivo therapy, and Repligen agrees to acquire BioLife Solutions for $1.5 billion
4 min read
This Week’s CGT News: First-in-Human Diabetes Cell Therapy
July 20, 2026
First-in-human diabetes cell replacement, early iPSC-derived CAR T data in systemic sclerosis, AAV gene therapy for fragile X syndrome, and fresh funding for off-the-shelf CAR T
4 min read
Smart Manufacturing Reaches the Bioprocessing Bench
July 14, 2026
Researchers retrofit a lab-scale monoclonal antibody purification platform with automation, OPC-UA connectivity, and model-based flow control
3 min read
